-- 週四上午晚些時候,美國存託憑證(ADR)上漲,歐洲股市在美國交易,標普歐洲精選ADR指數上漲2.20%,至1,818.51點。 歐洲大陸方面,領漲的股票包括製藥公司諾和諾德(NVO)和荷蘭國際集團(ING),分別上漲5.3%和4.9%。緊隨其後的是生物製藥公司基立福(GRFS)和消費品公司聯合利華(UL),分別上漲3.2%和3.1%。 歐洲大陸方面,領跌的股票包括網路廣告公司Criteo(CRTO)和電信公司諾基亞(NOK),分別下跌3.2%和1.9%。 英國方面,領漲的股票包括郵輪業者嘉年華(CUK)和公用事業公司國家電網(NGG),分別上漲4.8%和3.5%。緊隨其後的是勞埃德銀行集團 (LYG) 和電信營運商沃達豐集團 (VOD),分別上漲 2.6% 和 2.3%。 在英國和愛爾蘭的下跌個股中,軟體公司 Endava (DAVA) 和 Bicycle Therapeutics (BCYC) 領跌,分別下跌 5.2% 和 2.3%。緊隨其後的是生物製藥公司 Amarin (AMRN) 和 Mereo BioPharma Group (MREO),分別下跌 1.3% 和 0.9%。
Related Articles
Research Alert: CFRA Maintains Buy Rating On Shares Of Intercontinental Exchange, Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:After digesting Q1 results, we reduce our 12-month target price by $15 to $205, reflecting a P/E of 23.1x our 2027 EPS estimate, a premium to ICE's 10-year average of 22.1x given an improving margin profile. With geopolitical uncertainty surging, we increase our 2026 EPS estimate by $0.66 to $8.36 and raise 2027's by $0.27 to $8.86. ICE's Q1 results demonstrate its competitive strength, with revenue growth accelerating across all three business segments in the face of heightened uncertainty and geopolitical tensions. The outlook remains positive, with total futures and options open interest hitting a new record just this week, suggesting Q1's momentum will persist. However, concerns about AI disruption continue to weigh on the stock, likely keeping valuation multiples compressed near term. Critically, there is little evidence of actual business deterioration, and we note fixed income recurring revenue has actually accelerated for four consecutive quarters.
Leerink Partners Lowers Labcorp Price Target to $340 From $347
Labcorp (LH) has an average rating of overweight and mean price target of $311.35, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $257.19, Change: $+0.05, Percent Change: +0.02%
Top Midday Gainers
Avalyn Pharma (AVLN), a clinical-stage drugmaker, said late Wednesday it has priced its upsized initial public offering of about 16.7 million shares at $18.00 apiece, targeting gross proceeds of about $300 million.Shares soared in their trading debut on Nasdaq, up over 50% at about $27.44 in afternoon trading, with intraday trading volume of over 3.65 million.Everspin Technologies (MRAM) reported Thursday an agreement with a US prime contractor to provide Toggle MRAM process technology and engineering services for United States Defense Industrial Base customers. The agreement is valued at $40.0 million and will run over two-and-a-half years.Shares surged 37% as intraday trading volume soared to over 12.6 million from a daily average of about 533,000.Viavi Solutions (VIAV) jumped 15% after its fiscal Q3 results and fiscal Q4 guidance exceeded market expectations.More than 15.1 million shares traded intraday, compared with a daily average of about 5.87 million.Price: $27.00, Change: $+9.00, Percent Change: +50.00%